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OBJECTIVE—This study investigated the effects of resveratrol,
a natural polyphenol with neuroprotective properties, on retinal
neuronal cell death mediated by diabetes-induced activation of
Ca
2/calmodulin-dependent protein kinase II (CaMKII).
RESEARCH DESIGN AND METHODS—Diabetes was in-
duced in C57BL/6 mice by ﬁve consecutive intraperitoneal injec-
tions of 55 mg/kg streptozotocin (STZ). Control mice received
buffer. All mice were killed 2 months after the injections, and the
extent of neuronal cell death, CaMKII, and phospho-CaMKII
protein expression levels and CaMKII kinase activity were exam-
ined in the retinas. To assess the role of CaMKII in the death of
retinal neurons, a small-interfering RNA (siRNA) or speciﬁc
inhibitor of CaMKII was injected into the right vitreous humor,
and vehicle only was injected into the left vitreous humor, 2 days
before death. Resveratrol (20 mg/kg) was administered by oral
gavage daily for 4 weeks, beginning 1 month after the ﬁfth
injection of either STZ or buffer.
RESULTS—The death of retinal ganglion cells (RGCs), CaMKII,
phospho-CaMKII protein levels, and CaMKII activity were all
greatly increased in the retinas of diabetic mice compared with
controls, 2 months after induction of diabetes. Terminal deoxy-
nucleotidyl transferase (TdT)-mediated dUTP nick-end labeling
(TUNEL)-positive signals co-localized with CaMKII- and phos-
pho-CaMKII immunoreactive RGCs. However, in addition to
CaMKII knockdown and inhibition by siRNA or a speciﬁc inhib-
itor, respectively, resveratrol provided complete protection from
diabetes-induced retinal cell death.
CONCLUSIONS—In the present study, resveratrol prevented
diabetes-induced RGC death via CaMKII downregulation, imply-
ing that resveratrol may have potential therapeutic applications
for prevention of diabetes-induced visual dysfunction. Diabetes
59:1825–1835, 2010
D
iabetic retinopathy is a major complication of
diabetes associated with vascular and neuronal
abnormalities, leading to severe visual dysfunc-
tion (1–3). Recent studies have emphasized the
importance of diabetes-induced neuronal damage in the
retina at an early stage of disease progression (2,3–7).
The apoptotic cells due to diabetes are likely to include
retinal ganglion cells (RGCs) and other neurons (8). There-
fore, the identiﬁcation of pharmacological targets for the
prevention of damage to RGCs from diabetes may provide
a potential therapeutic strategy for diabetes-induced vi-
sion loss.
Ca
2/calmodulin-dependent protein kinase II (CaMKII)
is a multifunctional serine-threonine protein kinase that is
implicated in a variety of neuronal functions (9–11).
Recently, it was found that CaMKII contributes to the
death of neuronal cells, including RGCs (10,12–14). How-
ever, CaMKII also promotes neuronal survival in response
to various stresses (15,16), and thus it has been proposed
that CaMKII is an important point of intersection for
different pathways involved in neuron-destroying diseases,
including diabetic retinopathy.
For prevention of vision loss due to neuronal and
vascular damage, topical or oral treatments with ocular
penetration are ideal therapies that have been developed
recently; in addition, several clinical studies have concen-
trated on the beneﬁcial effects of natural polyphenols,
such as resveratrol (17,18). Resveratrol is a plant-derived
phytoalexin with diverse health beneﬁts, including protec-
tion from metabolic disorders, such as diabetes (19–21).
Although many studies have shown neuroprotective ef-
fects of resveratrol in in vitro experimental optic neurop-
athy (22,23), the effects of resveratrol on retinal neuron
damage due to diabetes are not known. Therefore, we
investigated whether resveratrol affects CaMKII-depen-
dent RGC death in diabetic mice and found that resvera-
trol can suppress CaMKII induction and thereby decrease
the extent of RGC death. Our results suggest that resvera-
trol may have powerful therapeutic applications for
prevention of CaMKII-mediated RGC death in diabetic
retinopathy.
RESEARCH DESIGN AND METHODS
Animals. Male C57BL/6 mice (Samtako, Osan, Korea), weighing 20–22 g (8
weeks old), were used in this study. All mice were maintained on a standard
rodent diet (20% protein, 4.5% fat, 6% cellulose, and 7.25% ash [containing 1.2%
calcium and 0.62% phosphorus] [#5057; Purina, Kyeonggi-Do, Korea]) and
water ad libitum and were handled in strict accordance with the Institutional
Animal Care and Use Committee of Gyeongsang National University.
For induction of diabetes, mice were injected intraperitoneally with 55
mg/kg streptozotocin (STZ; Sigma, St. Louis, MO) dissolved in 50 mmol/l
sodium citrate (pH 4.5), once a day for 5 consecutive days, and sex- and
age-matched control mice received buffer alone. All mice were killed 2 months
after the injections. Blood samples were obtained by tail puncture after a 2-h
fasting period, and the blood glucose levels were measured using a glucometer
(Precision, U.K.). Diabetes was conﬁrmed by blood glucose levels 13.9
mmol/l, 1 week after the ﬁfth injection of STZ. Body weights and blood
glucose levels in mice were recorded every 2 weeks.
Administration of resveratrol. Resveratrol (trans-3,4,5-trihydroxystilbene;
category R5010; Sigma; 20 mg/kg) was suspended in 0.5% carboxymethylcel-
lulose (CMC; Sigma) dissolved in 0.9% saline. This solution was administered
by oral gavage once a day for 4 weeks, beginning 1 month after the ﬁfth
injection of STZ or buffer, and 0.5% CMC was given as a control. Finally, mice
were assigned to four groups (that is, control and diabetic mice treated with
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weights and blood glucose levels were recorded every 2 weeks.
Assay kits and antibodies. To detect cell death, we used terminal deoxy-
nucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL)
assay kits with two different detection modes: Converter-POD and TMR red
(In Situ Cell Death Detection kits; Roche, Mannheim, Germany, respectively).
CaMKII activity was examined using the CaMKII Kinase Assay Kit from
Upstate (Temecula, CA), and an enhanced chemiluminescent (ECL) kit was
obtained from Amersham Biosciences (Little Chalfont, U.K.). Mouse and
rabbit monoclonal antibodies to CaMKII, phospho-CaMKII (T286), active
caspase-3, and gamma synuclein (-Syn; the ganglion cell marker) were
purchased from Abcam (Cambridge, U.K.). Mouse monoclonal antibodies
against -tubulin and pro-caspase-3 were obtained from Sigma. Secondary
horseradish peroxidase (HRP)-conjugated anti-mouse and -rabbit IgGs for
Western blotting, a biotinylated anti-rabbit IgG for immunohistochemistry,
and Qdot 525 goat F(ab)2 and Alexa Fluor 594 goat anti-mouse IgGs or Alexa
Fluor 350 and 488 goat anti-rabbit IgGs for immunoﬂuorescent staining were
purchased from Pierce (Rockford, IL), Molecular Probes (Eugene, OR), Vector
Laboratories (Burlingame, CA), and Invitrogen (Carlsbad, CA), respectively.
Western blot analysis. Protein extraction and Western blot analyses were
performed as described previously (24). Total protein (30 g) from the retinas
of each group of mice was subjected to 10% SDS-PAGE and then transferred
to a nitrocellulose membrane (Millipore). The blots were incubated consecu-
tively in primary antibody against CaMKII, phospho-CaMKII, and pro- or active
caspase-3 as well as an HRP-conjugated anti-rabbit IgG, and the target
proteins were visualized using an enhanced chemiluminescent kit. Each blot
was reprobed with -tubulin and pro-caspase-3 to control for differences in
loading. The fold changes in protein levels compared with controls, normal-
ized to -tubulin or pro-caspase-3, are indicated below the blots and as a bar
graph. Data are representative of four independent tests.
Measurement of changes in retinal morphology. Two months after
injection of STZ or buffer, 10-m frozen retinal sections were prepared as
described previously (25). To assess retinal morphological changes, the
sections were stained with hematoxylin and eosin (H&E), and retinal thick-
ness was measured as the length (m) from the ganglion cell layer (GCL) to
the tip of the inner nuclear layer. A comparative analysis of the retinal
thicknesses in diabetic and control groups was performed using four different
ﬁelds in four different regions of each retina.
Immunohistochemical staining. Immunohistochemistry was performed in
the sectioned retinas as described previously (25). After blocking with serum,
the sections were incubated in primary antibody against CaMKII or phospho-
CaMKII, a biotinylated secondary anti-rabbit IgG, and an avidin-biotinylated
HRP complex (ABC; Vector Laboratories), consecutively. To visualize immu-
noreactivity to CaMKII, the sections were developed using 0.025% 3,3-
diaminobenzidine tetrahydrochloride (DAB; Sigma)/0.003% H2O2 and
counterstained with cresyl violet to dye neuronal cells. To conﬁrm whether
the immunopositive cells of CaMKII and phospho-CaMKII were RGCs, we
performed double-immunoﬂuorescent staining as described previously (24)
for CaMKII or phospho-CaMKII and -Syn. Retinal sections were incubated
consecutively in Image-iT FX signal enhancer (Molecular Probes) for 10 min,
a mixture of primary antibodies for 2 h, and a mixture of Alexa Fluor 350 and
594 goat anti-rabbit and mouse IgGs for 1 h. The sections were then
counterstained with the nuclear marker 40,6-diamidino-2-phenylindole dihy-
drochloride (DAPI; Invitrogen) and wet-mounted in ProLong Gold antifade
reagent (Invitrogen).
Evaluation of cell death using TUNEL assays. Cell death was analyzed in
the retinal cryosections using the TUNEL assay kit with Converter-POD
according to the manufacturer’s directions. The sections were ﬁxed in 10%
fresh formaldehyde for 20 min at room temperature, washed three times in 100
mmol/l PBS (PBS; pH 7.4) for 3 min, incubated in blocking solution (3% H2O2
in methanol) for 10 min, permeabilized in 0.1% Triton X-100 with 0.1% sodium
citrate in PBS for 5 min on ice, and washed again in PBS. The ﬁxed and
permeabilized sections were covered with paraﬁlm and consecutively incu-
bated in the TUNEL reaction mixture for 1 h and Converter-POD for 30 min at
37°C. After washing in PBS, the signal-converted sections were developed
using DAB substrate with H2O2 in PBS and counterstained with cresyl violet.
To conﬁrm whether the TUNEL-positive cells are RGCs or phospho-CaMKII–
immunopositive cells, we sequentially performed immunoﬂuorescent staining
as described previously (24) for -Syn and phospho-CaMKII and the TUNEL
assay with TMR red according to the manufacturer’s directions on the same
cryosections. Retinal sections were incubated consecutively in signal en-
hancer, primary antibody for -Syn, and phospho-CaMKII for 2 h and Alexa
Fluor 488 goat anti-rabbit IgG for 1 h. The sections were then stained with the
TUNEL reaction and counterstained with DAPI. To determine the correlation
between RGC death and CaMKII or phospho-CaMKII expression, double-
immunoﬂuorescent staining for CaMKII or phospho-CaMKII and -Syn, using
Qdot 525 and Alexa Fluor 350 goat anti-mouse and rabbit IgGs and the TUNEL
reaction, were sequentially performed as mentioned above. All reactions were
performed in a moist chamber to prevent evaporative loss. The total number
of TUNEL- and CaMKII or phospho-CaMKII–positive RGCs was counted in the
GCL (100 m) in four different ﬁelds from three different retinas for each
group.
Knockdown and inactivation of CaMKII. For knockdown of CaMKII, we
performed target gene silencing with a small-interfering RNA (siRNA). The
sequence of CaMKII siRNA for silencing the mouse CaMKII was designed
using the Turbo si-Designer program (Bioneer; Daedeok-gu, Daejeon, Korea),
and the siRNA duplex was purchased from Bioneer. The sense and antisense
sequences of the siRNA were as follows: 5-UGAUCGAAGCCAUAAG
CAA(dTdT)-3 (sense) and 5-UUGCUUAUGGCUUCGAUCA(dTdT)-3 (anti-
sense). The siRNA duplex was completely dissolved in RNase-free distilled
water at a ﬁnal concentration of 1 mmol/l and diluted again to 1/10 and 1/100
(0.1 and 0.01 mmol/l). To select the best condition for siRNA gene silencing,
2 l each siRNA diluent were carefully injected into the right vitreous humors
of mice 2 months after induction of diabetes, and 2 l distilled water was
injected into the left vitreous humors as controls as described previously (7).
Mice were killed 0, 1, 2, and 4 days after the injections, and the efﬁciency of
the siRNA was determined by Western blotting of CaMKII. Data are represen-
tative of four independent tests.
To examine the effects of CaMKII inhibition, a myristoylated autocamtide-
2–related inhibitory peptide (AIP) (Biomol, Plymouth Meeting, PA), a highly
speciﬁc and potent inhibitor of CaMKII, was completely dissolved in sterile
PBS (pH 7.4) at a ﬁnal concentration of 500 mol/l. AIP (2 l) was injected
into the right vitreous humors of mice 2 months after induction of diabetes,
and PBS was injected into the left vitreous humors as controls. The efﬁciency
of the AIP was determined by Western blotting of CaMKII 0, 1, 2, and 4 days
after the injection. Data are representative of four independent tests.
Finally, 1 mmol/l siRNA or 500 mol/l AIP was injected intravitreally into
the retinas of mice 2 months after injection of STZ or buffer, and changes in
the expression levels of CaMKII and phospho-CaMKII, the kinase activity of
CaMKII, and the extent of cell death by CaMKII knockdown and inhibition
were evaluated after 2 days of treatment.
CaMKII kinase assay. CaMKII kinase activity was analyzed in 100 g total
protein from each retina by the CaMKII Kinase Assay Kit (Upstate) according
to the manufacturer’s directions with autocamtide-3 as a speciﬁc substrate for
CaMKII. CaMKII was stimulated with buffer containing 40 mmol/l HEPES, 1
mmol/l Mg-acetate, 100 mol/l EGTA, 200 mol/l Ca
2,5 0mol/l ATP, and 10
mol/l calmodulin. The reaction was initiated by the addition of calmodulin
and terminated by the addition of 1 mmol/l EGTA at the indicated times. The
results are reported as total enzyme activity in the presence of exogenous
Ca
2 and calmodulin and expressed in picomoles phosphate incorporated into
TABLE 1
Changes in body weight and blood glucose level with resveratrol treatment
Body weight (g) Blood glucose (mmol/l)
C-C C-R D-C D-R C-C C-R D-C D-R
Week 0 28.3  0.3 27.7  0.5 21.2  0.5 20.4  0.4 8.7  0.1 9.0  0.3 25.4  0.8 27.5  0.9
Week 2 27.6  0.3 26.3  0.4 21.1  0.6 21.1  0.5 9.0  0.2 7.4  0.2 31.8  0.7 29.6  0.8
Week 4 28.5  0.3 27.8  0.4 20.6  0.6 21.2  0.5 8.3  0.2 7.9  0.2 31.2  0.8 27.7  1.2*
Data are means  SE (n 	 10). Resveratrol (in 0.5% CMC) at a dose of 20 mg/kg of body weight and 0.5% CMC alone were administered daily
to control and diabetic mice, respectively, by oral gavage for 4 weeks. Time points were 0, 2, and 4 weeks after administration of resveratrol
and CMC to control and diabetic mice, respectively, 1 month after STZ treatment: C-C and C-R, CMC- and resveratrol-treated control mice,
respectively; D-C and D-R, CMC- and resveratrol-treated diabetic mice, respectively. *P 
 0.05 compared with CMC- and resveratrol-treated
diabetic groups.
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FIG. 1. Determination of retinal thickness and neuronal cell death in retinas of mice 2 months after induction of diabetes compared with control
mice. For morphological analysis, H&E staining was performed on 10-m retinal cryosections of control (A) and diabetic (B) mice. Retinal
thickness was measured as the length (in m) from the GCL to the tip of the INL, and the results were obtained from comparative analysis of
four different images of each retina (C). To assess cell death induced by diabetes in the retinas, Western blotting using an antibody to active
caspase-3 was performed for the retinas of both groups (D). An immunoblot with an antibody to active caspase-3 was reprobed with an antibody
to pro-caspase-3 to control for differences in loading, and the level of each protein was normalized to that of pro-caspase-3. Four independent
tests were repeated in different retinal extracts from each group, and the results are indicated as the fold change (E). To investigate retinal
neuron death, the TUNEL assay was performed on retinal sections from control and diabetic mice, followed by counterstaining with cresyl violet
(F and G). To conﬁrm the death of RGCs, immunoﬂuorescent staining of -Syn, the GC marker, using Alexa Fluor 488 goat anti-rabbit IgG (green)
and TUNEL staining were performed consecutively on the same sections from diabetic mice, and the sections were counterstained with the
nuclear marker DAPI (H–J). The total number of TUNEL
 RGCs was counted in four different ﬁelds of the GCL (100 m) from three different
retinas of each group (K). Data are means  SE (n  4). *P < 0.05 comparing control and diabetic groups. CTL and DM, control and diabetic mice
2 months after injection of buffer or STZ; INL, inner nuclear layer; IPL, inner plexiform layer; IS, inner segment; ONL, outer nuclear layer; OPL,
outer plexiform layer. Bars, 12.5 m. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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dent tests were repeated in different retinal extracts for each group.
Image capture and statistical analyses. All retinal images were captured at
a distance of 0.8–1 mm from the optic nerve head using an IX2-DSU disk
scanning biological microscope (Olympus, Wendenstrasse, Hamburg, Ger-
many). Quantitative analyses were performed using the Soft Imaging System
(System, Mu ¨nster, Germany) and SigmaGel 1.0 software (Jandel Scientiﬁc,
Erkrath, Germany), and bar graphs were constructed using SigmaPlot 4.0
(SPSS, Chicago, IL). All data are representative of four independent values and
presented as means  SE. Statistical analyses were performed nonparametri-
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FIG. 2. Molecular and morphological expression of CaMKII and phospho-CaMKII (Thr286), and CaMKII kinase assay in retinas of mice 2
months after induction of diabetes compared with controls. Protein levels of CaMKII and phospho-CaMKII were assessed by Western
blotting using 30 g total protein from each retina, and representative blots from four independent Western blots are shown in A. The
immunoblots were reprobed with -tubulin to control for differences in loading, and levels of each protein were normalized to that of
-tubulin. The results indicate the fold change in B and C, respectively. Analysis of CaMKII kinase activity was performed in the same
retinal homogenates (100 g) prepared for immunoblotting using the CaMKII Kinase Assay Kit. The results are expressed as picomoles of
phosphate incorporated into the CaMKII substrate peptide per minute per milligram total protein, and four independent tests were
repeated with different retinal extracts for each group (D). Data are means  SE (n  4). *P < 0.05 comparing control and diabetic groups.
To conﬁrm the distribution of CaMKII (E and F) and phospho-CaMKII (G and H) in retinal neuronal cells from control and diabetic mice,
retinal cryosections were immunostained with each antibody and then counterstained with cresyl violet. Arrows indicate immunopositive
signals of CaMKII and phospho-CaMKII in the GCL of the diabetic retina, and arrowheads in each insert show the double-immunoﬂuorescent
staining of -Syn and CaMKII or phospho-CaMKII, using Alexa Fluor 350 (blue) and 594 (red) goat anti-rabbit and mouse IgGs (F and H).
CTL and DM, control and diabetic groups 2 months after injection of buffer or STZ; INL, inner nuclear layer; IPL, inner plexiform layer; ONL,
outer nuclear layer; OPL, outer plexiform layer. Bars, 12.5 m. (A high-quality digital representation of this ﬁgure is available in the online
issue.)
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P value of 
0.05 was considered statistically signiﬁcant.
RESULTS
Control mice exhibited a sustained increase in body
weight (g) from the beginning to the end of the study
period (21.5  0.38 to 29.4  0.55, P 
 0.05, n 	 10), but
diabetic mice showed no signiﬁcant change in weight
(data not shown). The blood glucose levels (mmol/l) of
diabetic mice increased markedly and steadily from 1
week to 2 months after induction of diabetes (23.3  1.53
to 31.2  0.87, n 	 10, respectively), although control mice
remained normoglycemic throughout the study. Adminis-
tration of resveratrol and CMC did not affect the body
weights of diabetic or control mice, or the blood glucose
levels of control mice; however, hyperglycemia was signif-
icantly decreased in resveratrol-treated diabetic mice com-
pared with CMC-treated diabetic mice after 2 months
(31.2  0.84 vs. 27.7  1.16 mmol/l; P 
 0.05, n 	 10)
(Table 1).
In H&E staining, mice showed a signiﬁcant decrease
(P 
 0.05, n 	 4) in the thicknesses of the inner retina,
from the GCL to the tip of the inner nuclear layer, by 13.3%
2 months after induction of diabetes compared with those
of controls (Fig. 1C). No diabetes-induced changes were
observed in the thicknesses of the outer retinal regions
(data not shown). In Western blot analysis of active
caspase-3 to conﬁrm cell death, protein levels were highly
increased (2.5-fold; P 
 0.05, n 	 4) in the retinas of
diabetic mice compared with controls (Fig. 1D and E).
TUNEL-positive signals were observed in the GCLs of the
diabetic retinas (arrows in Fig. 1G) compared with con-
trols (Fig. 1F) and speciﬁc to RGCs (arrows in Fig. 1J). The
number of TUNEL-positive RGCs was greatly increased
(4.4-fold; P 
 0.05, n 	 4) in the diabetic retinas compared
with controls (Fig. 1K).
In Western blotting with CaMKII antibody, we observed
two bands (45 and 54 kDa) for CaMKII protein (Fig. 2A),
indicating its  and  forms, and the molecular level of
CaMKII was considered the total amount of both forms.
Protein levels of both CaMKII and phospho-CaMKII (50
kDa) were greatly increased (2.9- and 2.6-fold; P 
 0.05,
n 	 4, respectively) in the retinas of diabetic mice
compared with controls (Fig. 2A–C). Likewise, CaMKII
kinase activity was signiﬁcantly greater (2.03-fold; P 

0.05, n 	 4) in the retinas of diabetic mice than in controls
(Fig. 2D). Immunoreactivities of CaMKII and phospho-
CaMKII increased in the GCLs of diabetic retinas (arrows
in Fig. 2F and H) compared with controls (Fig. 2E and G)
and were speciﬁc to RGC cells (arrowheads in inserts)
(Fig. 2F and H).
Figure 3 shows that not only were all TUNEL-positive
cells RGCs but also the apoptotic RGCs were CaMKII or
phospho-CaMKII immunopositive in the retinas of diabetic
mice (arrows in Fig. 3B and E), while the RGCs of control
mice were not (Fig. 3A and D). The number of RGCs
co-stained for TUNEL and CaMKII or phospho-CaMKII
was greater (2.8- or 5.3-fold; P 
 0.05, n 	 4, respectively)
in diabetic retinas than in controls (Fig. 3C and F).
Treatment with siRNA efﬁciently decreased the level of
CaMKII protein in a dose- and time-dependent manner and
was greatest 2 days after treatment with 1 mmol/l siRNA at
the various dosages and times studied (Fig. 4A and B).
Interestingly, suppression of CaMKII by siRNA injection
signiﬁcantly reduced the level of active caspase-3 in reti-
nas of mice 2 months after induction of diabetes; 2 days
after treatment, the levels were 1.9-, 2.1-, 1.6-, and 2.5-fold
lower, respectively, in siRNA-injected diabetic mice com-
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 0.05,
n 	 4) (Fig. 4C–F). However, siRNA had no effect on
control mice.
A speciﬁc CaMKII inhibitor, AIP (500 mol/l), did not
affect the level of CaMKII protein but greatly diminished
the level of phospho-CaMKII in a time-dependent manner
in the retinas of mice 2 months after induction of diabetes
(Fig. 5A). The maximum decrease in the level of phospho-
CaMKII protein was observed 2 days after the treatment
at the various times studied. Finally, treatment with 500
mol/l AIP greatly decreased the level of phospho-
CaMKII protein, CaMKII kinase activity, and the level of
active caspase-3 in the retinas of mice 2 months after
induction of diabetes. Levels in AIP-treated diabetic
mice were similar to those observed in control mice 2
days after injection (2.5-, 2-, and 5.5-fold lower, respec-
tively, than in the PBS-treated diabetic group, P 
 0.05,
n 	 4) (Fig. 5B–E). However, AIP had no effect on
control mice.
Resveratrol treatment for 4 weeks blocked the increases
in CaMKII and phospho-CaMKII protein levels and CaMKII
kinase activity in the retinas of mice 2 months after
induction of diabetes. Levels of CaMKII, phospho-CaMKII,
and CaMKII activity were 1.7-, 1.8-, and 2-fold lower,
respectively, in resveratrol-treated diabetic mice com-
pared with CMC-treated diabetic mice (P 
 0.05, n 	 4)
(Fig. 6A–D). Resveratrol also prevented the increase in the
number of CaMKII and phospho-CaMKII immunopositive
RGCs (arrows and arrowheads) in the retinas of mice 2
months after induction of diabetes, maintaining levels
similar to those of controls. Levels of CaMKII and phos-
pho-CaMKII were 2.2- and 3-fold lower, respectively, in
resveratrol-treated diabetic mice compared with CMC-
treated diabetic mice (P 
 0.05, n 	 4) (Fig. 6H and L).
Lastly, we found that resveratrol effectively prevented
the increase in the level of active caspase-3 protein and the
number of cells co-stained for TUNEL and phospho-
CaMKII (arrows in Fig. 7D and E) in the retinas of mice 2
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FIG. 4. Changes in CaMKII and phospho-CaMKII protein levels, kinase activity of CaMKII, and the level of active caspase-3 protein after CaMKII
knockdown using RNA interference in retinas of mice 2 months after induction of diabetes compared with controls. siRNA (2 l) was injected into
the right vitreous of the retinas, and an equal volume of distilled water was injected into the left vitreous as a control. A and B: Dose- and
time-independent effects of siRNA on the level of CaMKII protein in the retinas of mice 2 months after the induction of diabetes, 2 days after
injection with 0.01, 0.1, or 1 mmol/l siRNA, and 0, 1, 2, and 4 days after injection with 1 mmol/l siRNA using immunoblotting. C–F: Changes in
CaMKII and phospho-CaMKII protein levels, CaMKII kinase activity, and active caspase-3 protein level in the retinas of control and diabetic
groups, 2 days after the injection of 1 mmol/l CaMKII siRNA. Each immunoblot was reprobed with -tubulin, and levels of the other proteins
were normalized to that of -tubulin. The fold changes in protein levels compared with the controls (CTL) are indicated below the blots (A–C)
or as a bar graph (F). DM, diabetic subjects. Results of the CaMKII kinase assay indicate the picomoles of phosphate incorporated into the
CaMKII substrate peptide per minute per milligram of total protein (D). All data show representative results from four independent tests and
are expressed as means  SE (n  4). *P < 0.05 and **P < 0.001 in A, comparing the DW-treated group with the others; *P < 0.05 and **P < 0.001
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caspase-3 and dying phospho-CaMKII–immunoreactive
RGCs (arrowhead in insert) were 2.4- and 2.6-fold lower,
respectively, in resveratrol-treated diabetic mice com-
pared with CMC-treated diabetic mice (P 
 0.05, n 	 4)
(Fig. 7F). However, resveratrol and CMC treatment did not
signiﬁcantly affect control or diabetic mice, respectively.
DISCUSSION
In the present study, we found that resveratrol effectively
prevented diabetes-induced RGC death and CaMKII up-
regulation in type 1 diabetic mice.
Some investigators have suggested that neuronal dam-
age in the retina could result from a reduction in retinal
thickness, and a progressive loss of retinal structure in
diabetes might contribute to the progression of diabetic
neuropathy, resulting in vision loss (26,27). In this study,
we conﬁrmed that diabetes induces not only a reduction in
inner retina thickness, including the GCL, but also the
death of RGC cells (Fig. 1). It appears that the death of
RGCs might be therefore linked to a decrease in the
thickness of the inner retina, indicating that diabetes-
induced retinal pathology occurred in our experimental
model of diabetes.
CaMKII activation is involved in physiological and
pathological events in neurons in an autophosphorylation-
dependent manner (28,29). In particular, CaMKII action in
damaged retinas is involved in the cell death pathway of
RGCs, resulting in visual dysfunction (12,13,16). In the
present study, we found that both total and phospho-
CaMKII protein levels were increased, along with CaMKII
activity, in retinas damaged by diabetes (Fig. 2). These
results indicate that activation of CaMKII kinase depends
on the elevated abundance of this enzyme in the diabetic
retina. CaMKII and phospho-CaMKII immunoreactivity
was detected only in RGCs throughout the retinas, and
dying TUNEL
 cells in the diabetic retinas were speciﬁc to
immunopositive RGCs (Fig. 3). Our results are in agree-
ment with those of many investigators who reported a
proapoptotic function of CaMKII in retinal neurons
(12,13,16). Phosphorylation of CaMKII has been known to
play a pivotal role in the function of this enzyme, and
CaMKII-selective siRNA (16,30) and potent inhibitors of
CaMKII, such as AIP (10,12), have been used as tools to
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(A high-quality digital representation of this ﬁgure is available in the online issue.)
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is known to confer neuroprotection on RGCs by inhibit-
ing CaMKII autophosphorylation (12–14). In the present
study, CaMKII siRNA and AIP treatments effectively pre-
vented CaMKII activation, and these treatments also effec-
tively attenuated RGC death induced by diabetes (Figs. 4
and 5). Together, our results indicate that diabetes-in-
duced RGC death is primarily mediated by CaMKII over-
expression and/or activation. However, CaMKII activation
by phosphorylation also contributes to neuronal survival
under certain conditions (15,16). For instance, activation
of CaMKII may be a neuroprotective response against
glutamate or its analog N-methyl-D-aspartate (NMDA)-
induced retinal neurotoxicity both in vitro and in vivo
(13,16). This discrepancy may be due to differences in
neuronal sensitivity against different pathophysiological
stimuli.
Recently, Deng et al. (31) suggested that resveratrol can
partly block hyperglycemia via the enhancement of glu-
cose uptake, and resveratrol is recognized as a potent
clinical therapeutic for the treatment of diabetes-induced
vascular dysfunction and cell death (32–34). Consistent
with these results, we found that resveratrol signiﬁcantly
diminished the elevation in blood glucose levels in mice 2
months after induction of diabetes, although resveratrol-
treated diabetic mice sustained a hyperglycemic state
(Table 1). Therefore, we cannot exclude the possibility
that resveratrol partially protects diabetes-induced retinal
damage through the reduction of blood glucose levels but
elicits effects that are not always coincident with the
control of hyperglycemia.
The antidiabetic metabolic effects of resveratrol have
been well documented in other organs besides the retina.
Sirtuin 1 (SIRT1) and activator of AMP-activated protein
kinase (AMPK), which are activated by resveratrol, have
been described as key contributors to the protective
effects of resveratrol in diabetic pathophysiology (19–
21,35). Furthermore, a recent study reported that resvera-
trol promotes AMPK activation by CaMK kinase (CaMKK)
(36). In a preliminary study, we examined effects of
resveratrol on SIRT1 and AMPK levels in retinas of mice 2
months after induction of diabetes. Finally, we found that
neither diabetes nor resveratrol affect SIRT1 action in our
animal model and that phospho-AMPK levels were greatly
lower in the retinas of diabetic mice than controls, and this
decline was reversed by resveratrol treatment; however,
phospho-AMPK levels in the retinas of resveratrol-treated
diabetic mice were still in a state of signiﬁcant decline
compared with controls (all data not shown). These re-
sults suggest that resveratrol partly contributes to AMP
kinase induction in our model; however, in the present
study, activation of CaMKII induced by diabetes in mouse
retinas was prevented and preserved at a basal level by
resveratrol treatment (Figs. 6 and 7). Therefore, we sug-
gest that AMPK is not likely to be a major target of
resveratrol in CaMKII-mediated cell death in our animal
experimental model. The discrepancy between our results
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in the pathophysiological conditions mediated by diabetes.
Recent studies have shown that resveratrol prevents
RGC damage in response to various stresses, including
oxidation and inﬂammation (22,23). Levels of cyclooxy-
genase-2 (COX-2) and inducible nitric oxide synthase
(iNOS), regarded as indicators of these stresses, are in-
creased in diabetic retinas in our model; these immunore-
activities were speciﬁc to vessels in retinas but not to
neurons, and resveratrol decreases the induction of COX-2
and iNOS in diabetic retinas (data not shown). These data
show that iNOS and COX-2 do not contribute to prevent
retinal neurons from diabetes-induced cell death in our
animal model, although we cannot rule out the possibility
that resveratrol may affect biological processes through a
reduction of oxidative stress and inﬂammation. Further,
the present study showed that the oral administration of
resveratrol effectively blocks the activation of CaMKII and
RGC death in retinas damaged by diabetes (Figs. 5–7). Xu
et al. (37) demonstrated that curcumin, another polyphe-
nol with resveratrol-like physiological properties, regu-
lates both CaMKII action and CaMKII-mediated RGC loss.
Many studies have assessed the neuroprotective effects of
natural polyphenolic components, including resveratrol,
on chronic diseases such as diabetes (22,23,37–39). In
addition, recent reports have indicated that a voltage-
gated calcium channel can modulate calcium-dependent
gene expression, including CaMKII, via activity-dependent
transcriptional regulation (40) and that activation of
CaMKII by voltage-gated calcium channels might contrib-
ute to the death of neuronal cells, including RGCs (41,42).
However, considerable evidence has suggested that the
protective effects of resveratrol from several stresses may
be related to the direct inhibition of Ca
2 inﬂux through
the blockade of a voltage-gated calcium channel (43,44).
Accordingly, we suggest that resveratrol might control
CaMKII expression and activity through interference of a
calcium- and voltage-gated calcium channel–dependent
process.
Taken together, our data show that CaMKII is a poten-
tial target for the treatment of vision loss due to diabetes-
induced neuropathy, and resveratrol is one such molecule
that elicits protective effects against diabetes-induced ret-
inal neuronal death via CaMKII suppression.
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